<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03262584</url>
  </required_header>
  <id_info>
    <org_study_id>KDP-001</org_study_id>
    <nct_id>NCT03262584</nct_id>
  </id_info>
  <brief_title>Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients</brief_title>
  <official_title>Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karius, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karius, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens,&#xD;
      is more accurate than other noninvasive options and can report fungal genomic load.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Sponsor aims to describe the incidence of positivity for fungal specific pathogens on NGS&#xD;
      analysis in a high-risk immunocompromised pediatric population.&#xD;
&#xD;
      Secondarily, the Sponsor will correlate results of the NGS analysis to other approved fungal&#xD;
      tests if performed at the discretion of the treating provider (e.g. blood culture results,&#xD;
      radiographic findings, biopsy results, bronchoalveolar lavage findings, galactomannan results&#xD;
      or b-D-glucan (BG) results as evaluated via FDA-approved &quot;Fungitell&quot; assay). The Sponsor will&#xD;
      use these other fungal tests, in addition to clinical criterion, to classify subjects as&#xD;
      having possible, probable and proven IFD according to established criteria, and compare these&#xD;
      categories against results from NGS analysis.&#xD;
&#xD;
      Lastly, to quantitatively evaluate follow-up test results to determine fungal DNA genomic&#xD;
      load in subjects with positive results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of positivity for fungal specific pathogens on NGS analysis</measure>
    <time_frame>7 months</time_frame>
    <description>We aim to describe the incidence of positivity for fungal specific pathogens on NGS analysis in a high-risk immunocompromised pediatric population.</description>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Invasive Fungal Disease</condition>
  <condition>Fever and Neutropenia</condition>
  <condition>Invasive Fungal Infections</condition>
  <condition>Immunocompromised</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients treated at Ann &amp; Robert H. Lurie Children's Hospital of Chicago on the&#xD;
        hematology, oncology, neuro-oncology and stem cell transplant unit&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prolonged FN (â‰¥96 hours) despite broad-spectrum antibiotic therapy with anticipated&#xD;
             delayed neutrophil recovery&#xD;
&#xD;
          -  Any findings that trigger the primary team to consider new fungal infection in a given&#xD;
             inpatient, such as abnormal imaging results, recrudescent fevers in the setting of&#xD;
             neutropenia or characteristic skin rashes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Those without concern for fungal infection or those currently being treated for a presumed&#xD;
        or documented fungal infection will not be recruited for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Armstrong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

